Trials / Recruiting
RecruitingNCT07152223
Clinical Study on the Safety and Efficacy of CD19-BCMA CAR-T Cell Therapy for Connective Tissue Diseases
A Single-center Clinical Study to Evaluate the Safety and Efficacy of CD19-BCMA CAR-T Cell Therapy for Connective Tissue Diseases
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Guangzhou Bio-gene Technology Co., Ltd · Industry
- Sex
- All
- Age
- 1 Year – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is a single-arm, single-center Investigator-Initiated Trial (IIT) designed to evaluate the safety, pharmacokinetic profile, and preliminary efficacy of CD19-BCMA CAR-T cells in subjects diagnosed with connective tissue diseases.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CAR-T | Eligible subjects who successfully passed screening will receive CAR-T cell infusion on Day 0 after lymphodepleting preconditioning chemotherapy. |
Timeline
- Start date
- 2025-08-30
- Primary completion
- 2029-08-31
- Completion
- 2029-08-31
- First posted
- 2025-09-03
- Last updated
- 2025-09-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07152223. Inclusion in this directory is not an endorsement.